Ph+ B-ALL (typically p190) requires TKI-incorporating regimens. Modern trials (D-ALBA, Fo...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BCR-ABL1-P190-BALL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-B-ALL |
| Sources | SRC-BLAST-GOKBUGET-2018 SRC-CIVIC SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-BCR-ABL1 |
|---|---|
| Variant | p190 (e1a2) — typical Ph+ B-ALL |
| Disease | DIS-B-ALL |
| ESCAT tier | IA |
| Recommended combinations | ponatinib + hyper-CVAD (1L), dasatinib + blinatumomab (D-ALBA chemo-light), imatinib + chemotherapy (1L alternative, lower-resource setting), ponatinib + blinatumomab (chemo-free regimen) |
| Contraindicated monotherapy | TKI alone without chemotherapy or immunotherapy backbone (insufficient durability) |
| Evidence summary | Ph+ B-ALL (typically p190) requires TKI-incorporating regimens. Modern trials (D-ALBA, Foà 2020; GIMEMA LAL2116) show dasatinib + blinatumomab achieves molecular CR in >60% with reduced chemotherapy. Ponatinib + hyper-CVAD (Jabbour 2024) and ponatinib + blinatumomab combos extend this further. TKI selection now favors ponatinib for highest molecular-response rates. |
Notes
ESCAT IA. Ponatinib preferred for highest molecular-response rates and to preempt T315I emergence. CNS prophylaxis essential. Allo-HCT consideration based on MRD response per ELN/NCCN.
Used By
No reverse references found in the YAML corpus.